To the Editor: I appreciated Brukner’s perspective on treatment of venous thromboembolism (VTE),1 but I do feel some additional considerations and clarifications are in order.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- Gold Coast Hospital — Robina, Robina, QLD.
Correspondence: James_Fink@health.qld.gov.au
- 1. Brukner PD. Stop taking warfarin? No way! Med J Aust 2009; 190: 704. <MJA full text>
- 2. Kearon C. Stopping anticoagulant therapy after an unprovoked venous thromboembolism. CMAJ 2008; 179: 401-402.
- 3. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008; 133 (6 Suppl): 454S-545S.
- 4. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417-426.
- 5. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789.
- 6. Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008; 149: 481-490.
- 7. Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism. Circulation 2007; 116: 1497-1503.
- 8. National Health and Medical Research Council Clinical Trials Centre. Aspirin to prevent recurrent venous thromboembolism (ASPIRE). http://www.ctc.usyd.edu.au/trials/other_trials/aspire.htm (accessed Sep 2009).
Online responses are no longer available. Please refer to our instructions for authors page for more information.